|
|||||
|
|
Analysis of multiple endpoints in clinical trials: it's time for the designations of primary,secondary and tertiary to go |
|
| Authors: | Steven Snapinn Qi Jiang |
| Institution: | Amgen, Department of Global Biostatistics and Epidemiology, Thousand Oaks, CA, USA |
| Abstract: | |
| Keywords: | |